Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Search
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US
Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Mental Health disorders
Mental Health disorders
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
US Privacy Statement
US Privacy Statement
Corporate Profile
Corporate Profile
Boehringer Ingelheim Invests in You
Oncology Partnering Interests | Boehringer Ingelheim US
Click here to view our range of downloads on Boehringer Ingelheim's oncology & cancer immunology partnering interests.
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Work life wellness
We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Our people
Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
Anna Race
Human Pharma Sales Director for UK & Ireland, Anna Race discusses how she enjoys making a difference within the company.
Cristian Torreblanca
Cristian Torreblanca Estrada, a Corporate GFE Senior Manager Controller in Germany talks about opportunities to move between professional areas and countries
Discovery Research Global Post-Doc Program
Discovery Research Global Post-Doc Program
Newsletter Subscription Confirmation
Newsletter : Thank you for subscribing
Human Health Products
Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.